Answers are grounded in this paper and cite their sources.
Literature reports on the risk of SARS-CoV-2 in people with inflammatory rheumatisms are inconsistent. According to most studies, the risk of infection and development of severe COVID-19 is higher in rheumatism patients versus the general population, but largely depends on rheumatism type and activity. Thus, patients with severe rheumatism most often required artificial ventilation and died more often. It was associated with immune dysfunction caused by both the disease itself and antirheumatic therapy with immunomodulating agents. Immunosuppression, additional chronic comorbidities, and incomplete vaccination are progression factors of COVID-19, hospital stay, intensive care, and risk factors of severe COVID-19 outcomes and reinfection with coronavirus in rheumatism patients. During the spread of SARS-CoV-2 Omicron variant, they were still significant. Although there is no full consensus in the literature regarding the association of rheumatism with the severity of COVID-19, rheumatism is usually not considered a factor of increased severity and mortality of COVID-19. SARS-CoV-2 vaccines boost humoral response, and reduce the incidence and severity of COVID-19. Nevertheless, rheumatism patients show reduced or no antibody production in response to even completed vaccination, along with higher rates of post-vaccination breakthrough infection. Further research into specific rheumatic diseases and the use of antirheumatic drugs in the context of COVID-19 is required to reduce the severity of COVID-19 in this population.
No takes yet. Share an insight, caveat, or question.
Sarana et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: